Zimmer Biomet Holdings, INC 8-K filings

Zimmer Biomet announced a 3.9% increase in second-quarter net sales, reaching $1.942 billion, and updated its full-year revenue guidance due to currency fluctuations while reaffirming constant currency revenue growth and adjusted EPS guidance.

Zimmer Biomet has entered into new credit agreements, replacing previous facilities with a $1.5 billion five-year and a $1 billion 364-day revolving credit agreement.

Zimmer Biomet has appointed Devdatt Kurdikar to its Board of Directors, increasing the board size from ten to eleven members.

Zimmer Biomet shareholders approved an amended Employee Stock Purchase Plan at the annual meeting on May 10, 2024, increasing the number of shares available and modifying plan provisions.

Zimmer Biomet announced a 3.2% increase in first-quarter net sales and reiterated its full-year 2024 financial guidance.

Zimmer Biomet announced a 6.3% increase in fourth-quarter net sales and a 6.5% increase in full-year net sales, alongside providing financial guidance for 2024.